Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alamin is a brand name for Metaraminol, a sympathomimetic medication primarily used as a vasopressor to prevent and treat hypotension, particularly as a complication of anesthesia. Its mechanism of action involves both indirect and direct effects. It primarily acts by displacing norepinephrine from neuronal vesicles, leading to an indirect sympathomimetic effect. Additionally, at higher doses, it directly stimulates alpha-1 adrenergic receptors, causing vasoconstriction, and exhibits some beta-1 adrenergic agonist effects, contributing to increased blood pressure and positive inotropy. It is administered intravenously or intramuscularly.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Alamin.